CDMO
Beyond's analysis on CDMO
- — Viva Biotech’s 2026 interim results show AI‑driven drug R&D and CDMO manufacturing lifting revenue 21% year‑on‑year
- — Insilico Medicine and Bora Pharmaceuticals team up to fuse AI-driven drug discovery with Bora’s development and manufacturing capabilities, aiming to accelerate novel therapy pipelines
Recent news mentioning CDMO
- — FIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUS
- — Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™
- — Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
- — Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
- — Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
- — Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
- — Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
- — Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization